肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2020 TSCRS共识：转移性结直肠癌细胞减灭术

2020-09-01 Ann Surg Oncol . 2020 Sep 1.

结直肠癌

2020年9月，台湾结直肠外科医师学会(TSCRS)发布了转移性结直肠癌细胞减灭术共识。文章最终共达成8条推荐意见，涉及转移灶切除标准，局部控制治疗的应用，同时性肝转移的管理，腹膜转移途径，多器官转移

中文标题：

2020 TSCRS共识：转移性结直肠癌细胞减灭术

英文标题：

Taiwan Society of Colon and Rectal Surgeons (TSCRS) Consensus for Cytoreduction Selection in Metastatic Colorectal Cancer

发布机构：

发布日期：

2020-09-01

简要介绍：

2020年9月，台湾结直肠外科医师学会(TSCRS)发布了转移性结直肠癌细胞减灭术共识。文章最终共达成8条推荐意见，涉及转移灶切除标准，局部控制治疗的应用，同时性肝转移的管理，腹膜转移途径，多器官转移的切除部位以及可切除性的一般标准。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020 TSCRS共识：转移性结直肠癌细胞减灭术.pdf)] GetToolGuiderByIdResponse(projectId=1, id=d7dbf1c0019ea434, title=2020 TSCRS共识：转移性结直肠癌细胞减灭术, enTitle=Taiwan Society of Colon and Rectal Surgeons (TSCRS) Consensus for Cytoreduction Selection in Metastatic Colorectal Cancer, guiderFrom=Ann Surg Oncol . 2020 Sep 1., authorId=0, author=, summary=2020年9月，台湾结直肠外科医师学会(TSCRS)发布了转移性结直肠癌细胞减灭术共识。文章最终共达成8条推荐意见，涉及转移灶切除标准，局部控制治疗的应用，同时性肝转移的管理，腹膜转移途径，多器官转移, cover=https://img.medsci.cn/2020923/1600870714299_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Tue Sep 01 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年9月，台湾结直肠外科医师学会(TSCRS)发布了转移性结直肠癌细胞减灭术共识。文章最终共达成8条推荐意见，涉及转移灶切除标准，局部控制治疗的应用，同时性肝转移的管理，腹膜转移途径，多器官转移的切除部位以及可切除性的一般标准。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=539, tagName=结直肠癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=76, categoryName=胃肠外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=539, guiderKeyword=结直肠癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2401, appHits=68, showAppHits=0, pcHits=588, showPcHits=2333, likes=1, shares=4, comments=6, approvalStatus=1, publishedTime=Wed Sep 23 23:08:53 CST 2020, publishedTimeString=2020-09-01, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Wed Sep 23 22:18:41 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 19:56:00 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 TSCRS共识：转移性结直肠癌细胞减灭术.pdf)])
2020 TSCRS共识：转移性结直肠癌细胞减灭术.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=978029, encodeId=b71c9e802977, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b35447270, createdName=ms4000000206232216, createdTime=Tue Jun 29 21:59:26 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978027, encodeId=55219e80279c, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b35447270, createdName=ms4000000206232216, createdTime=Tue Jun 29 21:54:57 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945223, encodeId=bb0b9452234d, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f85464656, createdName=ms2000000050996988, createdTime=Wed Mar 03 19:07:13 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889262, encodeId=6dca889262dd, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0de05113788, createdName=1461ef8em91暂无昵称, createdTime=Tue Sep 29 19:05:12 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2021-06-29 ms4000000206232216

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=978029, encodeId=b71c9e802977, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b35447270, createdName=ms4000000206232216, createdTime=Tue Jun 29 21:59:26 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978027, encodeId=55219e80279c, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b35447270, createdName=ms4000000206232216, createdTime=Tue Jun 29 21:54:57 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945223, encodeId=bb0b9452234d, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f85464656, createdName=ms2000000050996988, createdTime=Wed Mar 03 19:07:13 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889262, encodeId=6dca889262dd, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0de05113788, createdName=1461ef8em91暂无昵称, createdTime=Tue Sep 29 19:05:12 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2021-06-29 ms4000000206232216

    很好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=978029, encodeId=b71c9e802977, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b35447270, createdName=ms4000000206232216, createdTime=Tue Jun 29 21:59:26 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978027, encodeId=55219e80279c, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b35447270, createdName=ms4000000206232216, createdTime=Tue Jun 29 21:54:57 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945223, encodeId=bb0b9452234d, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f85464656, createdName=ms2000000050996988, createdTime=Wed Mar 03 19:07:13 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889262, encodeId=6dca889262dd, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0de05113788, createdName=1461ef8em91暂无昵称, createdTime=Tue Sep 29 19:05:12 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2021-03-03 ms2000000050996988

    关注

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=978029, encodeId=b71c9e802977, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b35447270, createdName=ms4000000206232216, createdTime=Tue Jun 29 21:59:26 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978027, encodeId=55219e80279c, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b35447270, createdName=ms4000000206232216, createdTime=Tue Jun 29 21:54:57 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945223, encodeId=bb0b9452234d, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f85464656, createdName=ms2000000050996988, createdTime=Wed Mar 03 19:07:13 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889262, encodeId=6dca889262dd, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0de05113788, createdName=1461ef8em91暂无昵称, createdTime=Tue Sep 29 19:05:12 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2020-09-29 1461ef8em91暂无昵称

    很好

    0

相关指南

2020 JSMO临床指南：结直肠癌治疗的分子检测（第4版）

日本肿瘤内科学会(JSMO,Japanese Society of Medical Oncology) · 2020-07-15

中国结直肠癌早诊早治专家共识

中华医学会肿瘤学分会 · 2020-06-09

中国结直肠癌骨转移多学科综合治疗专家共识（2020 版）

中国医师协会结直肠肿瘤专委会 · 2020-06-30

中国结直肠癌诊疗规范（2020年版）

中华人民共和国国家卫生健康委员会 · 2020-06-30

中国结直肠癌卵巢转移诊疗专家共识（2020版）

中国医师协会结直肠肿瘤专委会 · 2020-04-30

中国结直肠癌脑转移多学科综合治疗专家共识（2020版）

中国医师协会结直肠肿瘤专委会 · 2020-04-30

拓展阅读

2010 BSG 中高危人群结直肠癌筛查与监测指南

英国胃肠病学会(BSG,British Society of Gastroenterology) · 2010-05-01

2010 结直肠癌肝转移诊断和综合治疗指南（V 2010）

中华医学会外科学分会 · 2010-06-01

2011 NICE 结直肠癌诊疗指南

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2011-01-01

2011NICE 结直肠癌高危人群（溃疡性结肠炎、克罗恩病、结直肠腺瘤患者）结肠镜监测指南

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2011-03-23

2011 规范结直肠癌术中缓释型氟尿嘧啶腹腔内化疗的专家共识

结直肠癌术中缓释型氟尿嘧啶腹腔内化疗共识专家组 · 2011-06-01

结直肠癌诊疗规范（2010年版）

中华人民共和国卫生部(MINISTRY OF HEALTH OF THE PEOPLE`S REPUBLIC OF CHINA) · 2011-12-20